Cannabics Pharmaceuticals receives “Intention to Grant a European Patent” notice for its System and Method for High Throughput Screening of Cancer Cells patent application

PR Newswire TEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020 TEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020 /PRNewswire/ — Cannabics Pharmaceuticals Inc.

Read more

Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19

WAKEFIELD, Mass., April 20, 2020 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased

Read more

Innovation Pharmaceuticals Aims to Develop First Drug for Approval in Prevention of Oral Mucositis in Head and Neck Cancer Patients as Phase 2 Clinical Trial of Brilacidin Completes

BEVERLY, Mass., (Uptick Newswire – October 26, 2017) – Innovation Pharmaceuticals Inc. (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company,

Read more